NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 13 September 2022, 09:30am

**Location:** Via Zoom Conference Call

## Attendees

Committee members present

1. Dr Jane Adam (Chair) Present for all items
2. Dr Rada Todd (Future chair - Observing) Present for all items
3. Dr Brian Shine (Vice-chair) Present for all items
4. Dr James Fotheringham (Future vice-chair) Present for items 1 to 5.1.3
5. Professor Abdallah Al-Mohammad Present for all items
6. Richard Ballerand Present for items 1 to 5.2.2
7. Dr Andrew Champion Present for all items
8. Ana Duarte Present for all items
9. Dr Steve Edwards Present for all items
10. Professor Khalida Ismail Present for items 1 to 6.1.3
11. Professor G.J. Melendez-Torres Present for all items
12. Dr Pratheeban Nambyiah Present for all items
13. Hugo Pedder Present for all items
14. Dominic Pivonka Present for all items
15. Alan Thomas Present for all items

NICE staff present

Janet Robertson, Associate Director Items 1 to 5.2.2

Henry Edwards, Associate Director Items 6 to 6.2.2

Pilar Pinilla-Dominguez, Associate Director Items 1 to 4.2.2

Thomas Feist, Project Manager Items 1 to 5.2.2

Jeremy Powell, Project Manager Items 6 to 6.2.2

Sally Doss, Heath Technology Assessment Adviser Items 1 to 4.2.2

Carl Prescott, Heath Technology Assessment Adviser Items 5 to 5.2.2

Louise Crathorne, Heath Technology Assessment Adviser Items 6 to 6.2.2

Janet Boadu, Heath Technology Assessment Analyst Items 1 to 4.2.2

Rachel Ramsden, Heath Technology Assessment Analyst Items 1 to 4.2.2

Albany Chandler, Heath Technology Assessment Analyst Items 5 to 5.2.2

Owen Harrison, Heath Technology Assessment Analyst Items 6 to 6.2.2

Madiha Adam, Associate Heath Technology Assessment Analyst Items 1 to 4.2.2

Alice Pritchard, Associate Heath Technology Assessment Analyst Items 1 to 4.2.2

Adam Storrow, Business Analyst, RIA Present for all items

Emily Eaton-Turner, Technical Analyst, Commercial Liaison Items 5 to 5.2.2

Neha Jiandani, Technical Analyst, Commercial Liaison Items 1 to 4.2.2

Catrin Austin, Technical Analyst, Managed Access Items 5 to 5.2.2

Hayley Garnet, Senior Medical Editor Items 1 to 4.2.2

Olivia Havercroft, Senior Medical Editor Items 5 to 5.2.2

Ruth Melville, Senior Medical Editor Items 6 to 6.2.2

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 5 to 5.1.3

Laura Marsden, Public Involvement Adviser, PIP Items 6 to 6.1.3

Mandy Tonkinson, Public Involvement Adviser, PIP Items 1 to 4.1.3

Rosalee Mason, Coordinator, MIP Items 1 to 4.1.3, 6 to 6.1.3

Lyn Davies, Coordinator, MIP Items 5 to 5.1.3

Laura Kelly, Administrator, COT Present for all items

Marcia Miller, Administrator, TA Items 1 to 4.2.2

Rumana Zaman, Administrator, TA Items 6 to 6.2.2

Ayla Hudson, Apprentice, Planning and Ops Items 5 to 5.2.2

External assessment group representatives present

Mark Corbett, Centre for Reviews and Dissemination and Centre for Health Economics -York, Items 1 to 4.1.3

Rob Hodgson, Centre for Reviews and Dissemination and Centre for Health Economics -York, Items 1 to 4.1.3

Thea Van Asselt, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.1.3

Robert Wolff, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.1.3

Nigel Armstrong, Kleijnen Systematic Reviews Ltd (KSR) Items 6 to 6.1.3

Susan O’Meara, Kleijnen Systematic Reviews Ltd (KSR) Items 6 to 6.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, CDF Clinical Lead, NHS England, Present for all items

Eluned Hughes, Patient expert, nominated by Jo’s Cervical Cancer Trust, items 1 to 4.1.3

Susan Lalondrelle, Consultant Clinical Oncologist, Clinical expert, nominated by MSD, items 1 to 4.1.3

Alexandra Taylor, Consultant in Clinical Oncology, Clinical expert, nominated by MSD, items 1 to 4.1.3

Jean Abraham, Professor of Precision Breast Cancer Medicine/Academic Honorary Consultant in Medical Oncology, Clinical expert nominated by Royal College of Physicians, items 5 to 5.1.3

Holly Heath, Patient expert nominated by Breast Cancer Now, items 5 to 5.1.3

Stuart McIntosh, Clinical Reader in Surgical Oncology/Honorary Consultant Surgeon Clinical expert nominated by Royal College of Physicians, items 5 to 5.1.3

Dave Chuter, Patient expert nominated by Guts UK, items 6 to 6.1.3

Wasat Mansoor, Consultant in Medical Oncology, Clinical expert nominated by BMS, items 6 to 6.1.3

Elizabeth Smyth, Consultant in Gastrointestinal Oncology Clinical expert nominated by Royal College of Physicians, items 6 to 6.1.3

Helen West, Patient expert nominated by Guts UK, items 6 to 6.1.3

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from committee members.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 9 August 2022.

### Appraisal of Pembrolizumab in combination with platinum-based chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]

* 1. Part 1 – Open session
     1. The chair welcomed the NHS, Clinical and Patient experts, external assessment group representatives, members of the public and company representatives from Merck Sharp & Dohme.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Alexandra Taylor declared a direct financial interest, having worked on an MSD advisory board in February 2022. Dr Taylor also declared an indirect financial interest as they have received an education grant in an unrelated area, and a direct non-financial interest due to being a council member for the International Gynae Cancer Scoiety (2020-present), council member and guidelines co-chair for the British Gynaecological Cancer Society. It was agreed that these declarations would not prevent Dr Taylor from providing expert advice to the committee.
* Dr Susan Lalondrelle declared an indirect non-financial professional and personal interest, due to conducting research on the use of pembrolizumab for other indications. Dr Lalondrelle also declared an indirect financial interest, as they have received educational and travel grants from MSD. It was agreed that these declarations would not prevent Dr Lalondrelle from providing expert advice to the committee.
* Eluned Hughes declared an indirect financial interest, as their organisation has received educational grants from MSD. It was agreed that this declaration would not prevent them from providing expert advice to the committee.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by the lead team – G.J Melendez-Torres (Cost), Khalida Ismail (Clinical) and Alan Thomas (Lay).
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD)
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10669>

### Appraisal of Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of early and locally advanced non-metastatic triple-negative breast cancer [ID1500]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Sharp & Dohme.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Radha Todd declared a direct financial interest, having been a member of a Pfizer advisory board between September and November 2021. It was agreed that this declaration would not prevent them from participating in this discussion.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by the lead team – Hugo Pedder (Cost) Jane Adam (Clinical) and Alan Thomas (Lay).
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10399>

### Appraisal of Nivolumab in combination for untreated advanced unresectable recurrent or metastatic oesophageal squamous cell carcinoma cancer [ID2712]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Bristol-Myers Squibb.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Elizabeth Smyth declared a direct non-financial interest as they are co-chair of the EORTC (European Organisation for Research and Treatment of Cancer) Gastric Cancer Taskforce; member of the ESMO Guidelines Committee and Senior author of the Gastric and Oesophageal guidelines. It was agreed that this declaration would not prevent them from providing expert advice in this discussion.
* Dr Wasat Mansoor declared a direct financial interest as they have received payments for advisory boards with BMS and MSD. It was agreed that this declaration would not prevent them from providing expert advice in this discussion.
* Dr Radha Todd declared a direct financial interest, having been a member of a Pfizer advisory board between September and November 2021. It was agreed that this declaration would not prevent them from participating in this discussion.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by the lead team – Abdallah Al-Mohammad (Clinical) and Brian Shine (Cost).
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10572>

### Date of the next meeting

### The next meeting of the Technology Appraisal Committee A will be held on Tuesday 11 October 2022 and will start promptly at 10am.